The Distribution Oligopoly — McKesson, Cencora, Cardinal · The GLP-1 & Bio Supply Chain — Peptides, Bioprocessing & Diagnostics
delisted
Catalent (acquired by Novo Holdings, Dec 2024)loading…
History0 bars
Reference only — fill-finish CDMO acquired by Novo Holdings at $63.50, $16.5B EV.
What they do
Reference only. Catalent was acquired by Novo Holdings December 2024 at $63.50/share, $16.5B enterprise value. Three fill-finish sites were sold directly to Novo Nordisk for GLP-1 production. No longer publicly investable — included to flag that GLP-1 fill-finish capacity has been partially internalized by Novo.